Project Details
Description
A Phase IB Study of Crizotinib in Combination with Pembrolizumab (MK-3475) in Patients with Untreated Advanced ALK-Translocated Non-Small Cell Lung Cancer
Status | Finished |
---|---|
Effective start/end date | 11/20/15 → 7/30/20 |
Funding
- PFIZER, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.